Mo1813 Epidemiology, Risk Factors and Systemic Manifestations of Crohn's Disease in the United States: A Population Based Study

2016 ◽  
Vol 150 (4) ◽  
pp. S783
Author(s):  
Emad Mansoor ◽  
Gregory S. Cooper ◽  
Jeffry Katz
2019 ◽  
Vol 25 (11) ◽  
pp. 1773-1779 ◽  
Author(s):  
David A Schwartz ◽  
Ignacio Tagarro ◽  
Mary Carmen Díez ◽  
William J Sandborn

Abstract Background Fistulas may arise as a relevant complication of Crohn’s disease (CD). Despite their clinical significance and the substantial burden imposed on patients, limited data are available on the epidemiology of fistulizing CD in the United States. Methods A systematic literature review was conducted to identify data published between 1970 and 2017 on the epidemiology of fistulas in patients with CD, with the aim to estimate the number of prevalent cases in the United States. Retrieved titles and abstracts were screened by 2 independent researchers for inclusion criteria (US population-based studies reporting data on the epidemiology of fistulizing CD). To validate the literature-based estimate, data from a US claims database (Truven Health MarketScan database) were analyzed. This database has broad geographic coverage, with health care data for >60 million patients during the period of the analysis. Results The literature search retrieved 7 articles for full-text review, and only 1 met the criteria for inclusion. This study described the cumulative incidence of fistulas in a CD population from Minnesota over 20 years. From the reported data, the estimated number of prevalent cases with fistulizing CD in the United States was ~76,600 in 2017 (~52,900 anal, ~7400 rectovaginal, ~2300 enterocutaneous, and ~14,100 internal). Analysis from the US health care database resulted in an estimated number of ~75,700 patients, confirming the robustness of the original estimate from the literature. Conclusions Based on 2 separate analyses, the estimated number of patients with fistulizing CD in the United States is ~77,000 patients.


PLoS ONE ◽  
2017 ◽  
Vol 12 (10) ◽  
pp. e0186643 ◽  
Author(s):  
Jessica L. Petrick ◽  
Baiyu Yang ◽  
Sean F. Altekruse ◽  
Alison L. Van Dyke ◽  
Jill Koshiol ◽  
...  

2019 ◽  
Vol 156 (6) ◽  
pp. S-724
Author(s):  
Emad Mansoor ◽  
Mohammed Z. Sheriff ◽  
Mohannad Abou Saleh ◽  
Emi Hayashi ◽  
Maneesh Dave ◽  
...  

2009 ◽  
Vol 75 (10) ◽  
pp. 976-980 ◽  
Author(s):  
Rebecca R. Cannom ◽  
Andreas M. Kaiser ◽  
Glenn T. Ault ◽  
Robert W. Beart ◽  
David A. Etzioni

The treatment costs for patients in the United States with inflammatory bowel disease (IBD) exceed 1.7 billion dollars/year. Infliximab, an antibody to tumor necrosis factor-α, has been extensively used to treat IBD, with 390,000 IBD patients receiving the drug since its FDA approval in 1998. We sought to determine the impact of infliximab on population-based rates of hospitalizations and surgical care for patients with IBD in the United States. We used data from the Nationwide Inpatient Sample to analyze patterns of hospital-based treatment provided to patients with IBD between 1998 and 2005. Data from this analysis were combined with census data to calculate trends in population-based rates of treatment. Overall rates of hospitalization for patients with Crohn's disease and ulcerative colitis increased significantly between 1998 and 2005 (5.1%/year and 3.4%/year respectively, P < 0.001 for each). During the same time period there were no changes in the overall rates of surgical care. The expanding use of infliximab has not significantly impacted the use of surgical procedures for patients with either ulcerative colitis or Crohn's disease, and rates of nonsurgical hospitalizations have actually increased. Even in the era of infliximab, surgical care remains a mainstay in the treatment of IBD.


2020 ◽  
Vol 158 (3) ◽  
pp. S39-S40
Author(s):  
Emad Mansoor ◽  
Mohannad Abou-Saleh ◽  
Muhammad Talal Sarmini ◽  
Vijit Chouhan ◽  
Miguel Regueiro ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document